Skip to content
value.today

CalciMedica, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Your own DCF model

A full discounted-cash-flow model of CalciMedica, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against its own history

CalciMedica, Inc.'s multiples at each month end with a market cap on file, Jan 2021 to Oct 2026, each against its own median.

Price to book

1.0×

Now below its median of 3.0×, in the bottom quarter of its range; range 0.4× to 6.0× over 16 months.

0×2×3×5×6×2023202420252026Price to book 1×Median 3×

As of Oct 30, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025—$-30 M$-21 M$0 M$-21 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024—$-14 M$-21 M$0 M$-21 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023—$-34 M$-26 M$0 M$-26 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022—$-8 M$-12 M$0 M$-12 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021—$-36 M$-32 M$0 M$-32 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020—$-28 M$-32 M$1 M$-33 M—SEC annual report (10-K, 20-F)